Critical appraisal of systematic review and meta-analysis

Publication Date

2017

Document Type

Research

Abstract

This study was presented with a 60-year old female, Filipino, known case of Hypertension and Heart Failure with Reduced Ejection Fraction (EF 39%), NYHA Functional Class III, maintained on an ARB, beta blocker, and mineralocorticoid receptor blocker. This study included a total of 48 trials - 27 of which randomized a total of 12,391 participants with Heart Failure with Reduced Ejection Fraction (HFrEF), while 4 trials randomized a total of 5,278 participants with Heart Failure with Preserved Ejection Fraction (HFpEF). The European Society of Cardiology, as well as the American College of Cardiology recommends ARNI as a replacement for ACE inhibitors in patients with heart failure with reduced ejection fraction who remain symptomatic despite optimal medical therapy. This study shows that the use of Sacubitril/Valsartan reduces the risk of all-cause mortality, serious adverse events, hospitalizations, and increases quality of life and ejection fraction.

This document is currently not available here.

Share

COinS